The 32nd Annual J.P. Morgan Healthcare Conference (January 13-16, 2014 - San Francisco, California, USA): Auxilium Pharmaceuticals.
CEO and President Adrian Adams described Auxilium Pharmaceuticals as "the same as a Big Pharma company, only smaller." This 'specialty biopharmaceutical company' has transformed itself in the last 6 to 9 months to become the "leading men's healthcare franchise with a broad and diverse product portfolio." All of this has led to a very busy 2013, which began with the USD 600 million acquisition (Q2) and integration of Actient Pharmaceuticals, the licensing of avanafil (Stendra™) for erectile dysfunction and ended with the approval of collagenase Clostridium histolyticum (Xiaflex®) in Peyronie's disease. From a portfolio of 2 products at the beginning of 2013, Auxilium ended the year with 12.
Thomson Reuters, London, UK. scientific.prousjournals@thomsonreuters.com.
J
J
Watt
D035843:Biomedical Research / Q000639:trends*; D001702:Biopharmaceutics; D047009:Hathewaya histolytica / Q000201:enzymology; D015195:Drug Design; D004345:Drug Industry / Q000639:trends*; D007172:Erectile Dysfunction / Q000188:drug therapy; D006801:Humans; D008297:Male; D003012:Microbial Collagenase / Q000008:administration & dosage
D003012:Microbial Collagenase
Alprostadil alfadex; Auxilium Pharmaceuticals; Avanafil; Collagenase Clostridium histolyticum; Testim®; Testopel®